These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23098258)

  • 21. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia.
    Yoon YS; Lee HJ; Yoon HI; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
    Int J Tuberc Lung Dis; 2005 Nov; 9(11):1215-9. PubMed ID: 16333927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
    Lee JH; Kim HJ; Kim YH
    J Korean Med Sci; 2017 Jan; 32(1):77-84. PubMed ID: 27914135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Tendon Injury in Patients Treated With Fluoroquinolone (FQ) Versus Non-Fluoroquinolone Antibiotics for Community-Acquired Pneumonia (CAP).
    Fleming VH; Xu J; Chen X; Hall D; Southwood RL
    Ann Pharmacother; 2024 Aug; 58(8):771-780. PubMed ID: 37946374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit.
    Nseir S; Di Pompeo C; Soubrier S; Delour P; Lenci H; Roussel-Delvallez M; Onimus T; Saulnier F; Mathieu D; Durocher A
    Crit Care Med; 2005 Feb; 33(2):283-9. PubMed ID: 15699829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.
    Long R; Chong H; Hoeppner V; Shanmuganathan H; Kowalewska-Grochowska K; Shandro C; Manfreda J; Senthilselvan A; Elzainy A; Marrie T
    Clin Infect Dis; 2009 May; 48(10):1354-60. PubMed ID: 19348594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial strategy for severe community-acquired legionnaires' disease: a multicentre retrospective observational study.
    Cecchini J; Tuffet S; Sonneville R; Fartoukh M; Mayaux J; Roux D; Kouatchet A; Boissier F; Tchir M; Thyrault M; Maury E; Jochmans S; Mekontso Dessap A; Brun-Buisson C; de Prost N
    J Antimicrob Chemother; 2017 May; 72(5):1502-1509. PubMed ID: 28204479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contributing factors to mortality rates of pulmonary tuberculosis in intensive care units.
    Tatar D; Senol G; Kirakli C; Edipoglu O; Cimen P
    J Chin Med Assoc; 2018 Jul; 81(7):605-610. PubMed ID: 29709560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cotrimoxazole for community-acquired urinary tract infections leads to more adverse effects than fluoroquinolones.
    Michelangeli C; Courjon J; Curlier E; Roger PM
    Infect Dis Now; 2021 Jun; 51(4):374-376. PubMed ID: 33975674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant pulmonary tuberculosis in hospitalized healthcare-associated pneumonia in a tuberculosis endemic area: a multi-center retrospective study.
    Feng JY; Fang WF; Wu CL; Yu CJ; Lin MC; Ku SC; Chen YC; Chen CW; Tu CY; Su WJ; Yang KY
    PLoS One; 2012; 7(5):e36832. PubMed ID: 22629334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current prospects for the fluoroquinolones as first-line tuberculosis therapy.
    Takiff H; Guerrero E
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5421-9. PubMed ID: 21876059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.
    Migliori GB; Langendam MW; D'Ambrosio L; Centis R; Blasi F; Huitric E; Manissero D; van der Werf MJ
    Eur Respir J; 2012 Oct; 40(4):814-22. PubMed ID: 22653774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study.
    Mongardon N; Max A; Bouglé A; Pène F; Lemiale V; Charpentier J; Cariou A; Chiche JD; Bedos JP; Mira JP
    Crit Care; 2012 Aug; 16(4):R155. PubMed ID: 22894879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
    Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
    BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefazolin versus fluoroquinolones for the treatment of community-acquired urinary tract infections in hospitalized patients.
    Uppala A; King EA; Patel D
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1533-1538. PubMed ID: 31114972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
    Mortensen EM; Restrepo MI; Anzueto A; Pugh J
    Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy.
    Gacouin A; Le Tulzo Y; Lavoue S; Camus C; Hoff J; Bassen R; Arvieux C; Heurtin C; Thomas R
    Intensive Care Med; 2002 Jun; 28(6):686-91. PubMed ID: 12107671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
    Lee H; Jeong BH; Park HY; Jeon K; Huh HJ; Lee NY; Koh WJ
    Antimicrob Agents Chemother; 2016 Jan; 60(1):471-7. PubMed ID: 26525801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.